Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIPHETAMINE 20 vs AZITHROMYCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Biphetamine 20 is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, and inhibit their reuptake, thereby increasing synaptic concentrations of these neurotransmitters in the central nervous system.
Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting m RNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.
Narcolepsy,Attention Deficit Hyperactivity Disorder (ADHD) (FDA-approved for these indications as a schedule II controlled substance)
Acute bacterial exacerbations of chronic obstructive pulmonary disease due to H. influenzae, M. catarrhalis, or S. pneumoniae,Acute bacterial sinusitis due to H. influenzae, M. catarrhalis, or S. pneumoniae,Community-acquired pneumonia due to C. pneumoniae, H. influenzae, M. pneumoniae, or S. pneumoniae,Pharyngitis/tonsillitis due to S. pyogenes,Uncomplicated skin and skin structure infections due to S. aureus, S. pyogenes, or S. agalactiae,Urethritis/cervicitis due to C. trachomatis or N. gonorrhoeae,Genital ulcer disease due to H. ducreyi,Acute otitis media due to H. influenzae, M. catarrhalis, or S. pneumoniae,Prevention of disseminated M. avium complex disease in advanced HIV infection,Pertussis (off-label)
10-20 mg orally once daily in the morning; may increase to 20 mg twice daily (morning and noon) if needed.
500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.
0.5–1.5 hours for the immediate-release component; terminal elimination half-life of the total amphetamine salts is approximately 10–13 hours in adults
Terminal half-life of approximately 68 hours (range 35–96 h) after multiple doses, allowing once-daily dosing and a prolonged post-antibiotic effect.
Metabolized primarily by the liver via CYP2D6 and to a lesser extent by CYP3A4. Major metabolic pathways include hydroxylation, deamination, and oxidation to benzoic acid derivatives. Excretion is primarily renal.
Primarily hepatic, not via cytochrome P450 system. Partially metabolized to inactive metabolites. Eliminated via biliary excretion and renal excretion (<15% unchanged).
Renal (90% as unchanged drug and metabolites, with approximately 30% unchanged); fecal (10%)
Primarily biliary/fecal (approx. 50% unchanged); renal excretion accounts for about 12% of the dose.
16–20% (primarily to albumin)
7–51% (concentration-dependent); primarily binds to albumin.
3–4 L/kg; indicates extensive tissue distribution
31.1 L/kg (range 23–50 L/kg), indicating extensive tissue penetration and sequestration (e.g., WBCs, liver, lung).
Oral: 75–100% (first-pass metabolism minimal)
Oral: 37–40% (fasting); food may decrease absorption by ~50%.
e GFR <30 m L/min: contraindicated; e GFR 30-59 m L/min: use with caution, reduce dose by 50%.
No dose adjustment required for GFR ≥10 m L/min. For GFR <10 m L/min, caution advised; no specific dose recommendation, consider alternative agent.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: use not recommended.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A and B). Contraindicated in severe hepatic impairment (Child-Pugh class C).
Children ≥6 years: initial 5 mg orally once daily; titrate by 5 mg weekly to max 20 mg/day.
For otitis media and community-acquired pneumonia: 10 mg/kg orally or IV on day 1 (max 500 mg), then 5 mg/kg (max 250 mg) once daily on days 2-5. For pharyngitis/tonsillitis: 12 mg/kg orally once daily for 5 days (max 500 mg/day).
Initiate at 5 mg orally once daily; increase slowly with monitoring for cardiovascular effects.
No specific dose adjustment required; use same dosing as younger adults. Monitor renal function due to age-related decline, but no modification needed unless severe renal impairment (Cr Cl <10 m L/min).
WARNING: ABUSE AND DEPENDENCE. Biphetamine contains amphetamine and dextroamphetamine, which have a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
None.
Cardiovascular: risk of sudden death or serious cardiovascular events, especially in patients with pre-existing cardiac abnormalities.,CNS effects: may cause psychotic or manic symptoms, aggression, seizures, and visual disturbances.,Growth suppression: may cause weight loss and growth retardation in children.,Peripheral vasculopathy: including Raynaud's phenomenon.,Serotonin syndrome: when co-administered with serotonergic drugs.,Potential for immediate hypersensitivity reactions.
Hepatotoxicity: hepatitis, cholestatic jaundice, hepatic necrosis, hepatic failure,QT prolongation and torsades de pointes (especially with concurrent use of other QT-prolonging agents, electrolyte abnormalities, bradycardia, or structural heart disease),Clostridioides difficile-associated diarrhea (CDAD),Aggravation of myasthenia gravis,Severe allergic reactions (angioedema, anaphylaxis, Stevens-Johnson syndrome),Infantile hypertrophic pyloric stenosis (IHPS) in neonates following oral azithromycin,Use in pregnancy: category B; avoid during breastfeeding due to potential for disruption of infant gut flora
Hypersensitivity to amphetamine or dextroamphetamine,Concurrent use or within 14 days of MAO inhibitors (hypertensive crisis risk),Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease (e.g., advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension),Motor tics or Tourette's syndrome (worsening possible)
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic,History of cholestatic jaundice or hepatic dysfunction associated with prior azithromycin use,Concurrent use with ergotamine or dihydroergotamine (possible ergot toxicity)
Avoid foods and beverages high in caffeine or other stimulants (e.g., coffee, tea, cola, chocolate) as they may increase stimulant effects and risk of adverse reactions. Acidic foods (e.g., citrus fruits, juices) and vitamin C can decrease absorption; separate intake by at least 1 hour. Maintain a consistent meal schedule to minimize appetite suppression.
Food does not significantly affect absorption; can be taken with or without food. However, avoiding high-fat meals may reduce minor GI side effects. No known specific food interactions.
First trimester: Limited data; possible increased risk of oral clefts and cardiovascular defects based on some studies. Second and third trimesters: Risk of prematurity, low birth weight, neonatal withdrawal syndrome, and potential for behavioral effects. Avoid use unless benefit outweighs risk.
FDA Category B. No evidence of teratogenicity in animal studies; limited human data show no increased risk of major malformations. First trimester: No significant association with birth defects. Second/third trimester: No reported fetal harm from short-term use for infections like chorioamnionitis. Use only if clearly needed.
Contraindicated in breastfeeding. Amphetamines are excreted in human milk (M/P ratio not established) and may cause infant agitation, poor feeding, and growth suppression. Discontinue drug or nursing.
Azithromycin is excreted into breast milk in low amounts. M/P ratio approximately 0.2-0.6. Relative infant dose estimated at 2-6% of maternal weight-adjusted dose. Generally considered compatible with breastfeeding; monitor infant for diarrhea or rash.
No established dosage adjustments in pregnancy; use lowest effective dose for shortest duration. Increased clearance during pregnancy may require dose increase, but safety data insufficient. Avoid in pregnancy unless essential.
No dose adjustment required for pregnancy. Standard adult dosing (500 mg on day 1, then 250 mg daily for 4 days) is appropriate. Note: Pregnancy may increase volume of distribution, but pharmacokinetic studies suggest no significant decrease in AUC; no need for dose increase.
Monitor for hypertension and tachycardia; avoid use in patients with cardiovascular disease, hyperthyroidism, or glaucoma. Use with caution in patients with a history of substance abuse. May exacerbate tics and Tourette syndrome. Do not administer late in the day due to insomnia risk. Discontinue if seizures occur.
Monitor for QTc prolongation especially in patients with preexisting cardiac conditions or those on other QT-prolonging drugs. Azithromycin has a long half-life (68 hours) allowing for shorter treatment courses. Use with caution in hepatic impairment; consider alternative in severe liver disease. Not recommended for pneumonia in patients with bacteremia due to increased mortality risk. Administer on an empty stomach or with food if GI upset occurs; however, absorption is unaffected by food.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Take the first dose upon awakening; avoid taking late in the day to prevent sleep problems.,Do not chew or crush tablets; swallow whole with water.,Avoid alcohol and caffeine while taking this medication.,Report any chest pain, palpitations, shortness of breath, or fainting immediately.,May cause dizziness or blurred vision; avoid driving until you know how it affects you.,Store at room temperature away from light and moisture.
Take exactly as prescribed; do not skip doses or stop early even if you feel better.,Do not take antacids containing aluminum or magnesium within 2 hours before or after this medication.,Report any signs of liver problems (nausea, vomiting, dark urine, jaundice) or severe diarrhea (watery or bloody) immediately.,Azithromycin may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Inform your doctor if you have a history of QT prolongation, heart rhythm problems, or electrolyte imbalances.,Store at room temperature away from moisture and heat; discard any unused liquid after 10 days.
No interactions on record
"Azithromycin, a macrolide antibiotic, is known to prolong the QT interval by blocking cardiac potassium channels (specifically IKr), which can lead to torsades de pointes. Mifepristone also poses a risk of QT prolongation, likely via similar mechanisms. Coadministration may result in additive QTc prolongation, increasing the risk of life-threatening ventricular arrhythmias, especially in patients with preexisting cardiac conditions or electrolyte disturbances."
"Lumiracoxib is a selective COX-2 inhibitor primarily metabolized by CYP2C9 and to a lesser extent by CYP3A4. Azithromycin, a macrolide antibiotic, is a known inhibitor of CYP3A4. Concomitant use may decrease the metabolism of azithromycin, leading to increased plasma concentrations and potential toxicity, such as QT prolongation and hepatotoxicity. Elevated azithromycin levels can also enhance its antibacterial effects but raise safety concerns."
"Azithromycin, a macrolide antibiotic, inhibits the cardiac potassium channel encoded by hERG (human Ether-à-go-go-Related Gene), leading to prolonged cardiac repolarization and increased risk of QTc interval prolongation. Arformoterol, a long-acting beta-2 agonist, can also prolong the QTc interval via beta-adrenergic receptor-mediated effects on cardiac ion channels. Concurrent use may result in additive QTc prolongation, predisposing patients to potentially fatal ventricular arrhythmias such as torsades de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIPHETAMINE 20 vs AZITHROMYCIN, answered by our medical review team.
BIPHETAMINE 20 is a Central Nervous System Stimulant that works by Biphetamine 20 is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, and inhibit their reuptake, thereby increasing synaptic concentrations of these neurotransmitters in the central nervous system.. AZITHROMYCIN is a Macrolide Antibiotic that works by Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting m RNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIPHETAMINE 20 and AZITHROMYCIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIPHETAMINE 20 is: 10-20 mg orally once daily in the morning; may increase to 20 mg twice daily (morning and noon) if needed.. The standard adult dose of AZITHROMYCIN is: 500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIPHETAMINE 20 and AZITHROMYCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIPHETAMINE 20 is classified as Category C. First trimester: Limited data; possible increased risk of oral clefts and cardiovascular defects based on some studies. Second and third trimesters: Risk of prematurity, low birth . AZITHROMYCIN is classified as Category A/B. FDA Category B. No evidence of teratogenicity in animal studies; limited human data show no increased risk of major malformations. First trimester: No significant association with . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.